CNNC Headway BNCT Boron Pharmaceutical, a subsidiary of China Tongfu (01763), was clinically approved

^{Zhitong Finance App News, China Tongshi (01763) issued an announcement. Recently, the China Drug Administration Drug Evaluation Center (CDE) official website information shows that the Class 2.2 improved new drug “Injectable [10 B] Falun Boron” (BNCT Boron Drug: Boron Neutron Capture Therapy, Boron Neutron Capture Therapy) clinical trial application was approved (Notification No.:} 2025LP03425).

The domestically produced “Boron for Injection [¹⁰ B] Falun” developed by CNNC Headway has significant clinical advantages for head and neck tumors that are insensitive, recurrent, refractory, invasive, intermediate to advanced, and locally metastatic head and neck tumors, and has a short treatment period (only 1-2 sessions) and low toxic side effects, representing the development direction and cutting-edge innovation of modern precision oncology medicine, providing patients with new treatment options and promoting innovation and breakthroughs in the field of tumor treatment.

Furthermore, the approval of CNNC Headway's “Boron for Injection [¹⁰ B] Falun” clinical trial application marks a breakthrough in the field of collaborative R&D of CNNC Headway's BNCT pharmaceutical devices, officially entering a new stage of clinical transformation, injecting new momentum in nuclear technology into precise tumor treatment under the “Healthy China” strategy, and contributing to the “China Plan” for global cancer treatment.